Clinical Trials Logo

Gastroesophageal Cancer clinical trials

View clinical trials related to Gastroesophageal Cancer.

Filter by:

NCT ID: NCT05122091 Recruiting - Gastric Cancer Clinical Trials

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

For locally advanced gastric/gastroesophageal junction adenocarcinoma (cT3/4aN+M0 ), neoadjuvant therapy can downstage T and N stage, improve R0 resection rate, reduce recurrence and metastasis rates, and finally improve the long-term survival. A combination of Fruquintinib and SOX for locally advanced gastric/gastroesophageal junction adenocarcinoma could be a novel therapy. This study intends to evaluate the efficacy of Fruquintinib plus SOX as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma.

NCT ID: NCT05098132 Recruiting - Gastric Cancer Clinical Trials

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Start date: January 25, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

NCT ID: NCT04688801 Recruiting - Esophageal Cancer Clinical Trials

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence, to continue with the chemotherapy± radiotherapy is often used in these cases. However, the overall survival is still poor. We designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. The primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.

NCT ID: NCT04681248 Available - Ovarian Cancer Clinical Trials

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Start date: n/a
Phase:
Study type: Expanded Access

An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.

NCT ID: NCT04602117 Withdrawn - Ovarian Cancer Clinical Trials

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.

NCT ID: NCT04555304 Not yet recruiting - Gastric Cancer Clinical Trials

Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of the study drug known as KH903 in participants with gastric and gastroesophageal cance

NCT ID: NCT04544046 Active, not recruiting - Lymphoma Clinical Trials

Supportive Oncology Care At Home RCT

Start date: September 16, 2020
Phase: N/A
Study type: Interventional

This research study is evaluating a program that entails remote monitoring and home-based care for people with cancer who are receiving chemotherapy, radiotherapy, or chemoradiotherapy.

NCT ID: NCT04510285 Terminated - Gastric Cancer Clinical Trials

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Start date: August 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.

NCT ID: NCT04504669 Active, not recruiting - Melanoma Clinical Trials

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Start date: August 18, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors

NCT ID: NCT04385641 Recruiting - Clinical trials for Gastroesophageal Cancer

Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer

Start date: October 8, 2019
Phase: N/A
Study type: Interventional

This study is an open, single infusion, cell infusion dose /method exploration study. In patients with gastric cancer and gastroesophageal cancer without effective treatment, the safety of UCB-NK cell immunotherapy was evaluated and the preliminary curative effect results were obtained.